Alessandro Villa1, Stephen T Sonis. 1. Division of Oral Medicine and Dentistry, Brigham and Women's Hospital Department of Oral Medicine, Infection and Immunity, Harvard School of Dental Medicine, Boston, Massachusetts, USA.
Abstract
PURPOSE OF REVIEW: Oral mucositis remains a frequent debilitating toxicity associated with drug and radiation regimens used to treat cancer. This review highlights the recent understanding of the biological basis, risk factors for, and management for oral mucositis. RECENT FINDINGS: Prevalence and incidence data for mucositis are inconsistent and often underreported. The pathogenesis of mucositis encompasses a sequence of biological events possibly influenced by the oral microbiome and environment. Despite its frequency and severity, there is currently no effective treatment available for the majority of patients at risk. However, with the better understanding of the pathogenesis of mucositis a number of new drugs and biological agents are under investigation. Genome-wide risk prediction tools will allow the identification of patients at risk of developing mucositis. SUMMARY: Oral mucositis is a common complication of cancer treatment that may negatively impact the patient's cancer treatment outcome. Despite its frequency and consequences, the lack of effective interventions has frustrated patients and caregivers. Fortunately, a broad range of mechanistically targeted compounds are being developed.
PURPOSE OF REVIEW: Oral mucositis remains a frequent debilitating toxicity associated with drug and radiation regimens used to treat cancer. This review highlights the recent understanding of the biological basis, risk factors for, and management for oral mucositis. RECENT FINDINGS: Prevalence and incidence data for mucositis are inconsistent and often underreported. The pathogenesis of mucositis encompasses a sequence of biological events possibly influenced by the oral microbiome and environment. Despite its frequency and severity, there is currently no effective treatment available for the majority of patients at risk. However, with the better understanding of the pathogenesis of mucositis a number of new drugs and biological agents are under investigation. Genome-wide risk prediction tools will allow the identification of patients at risk of developing mucositis. SUMMARY:Oral mucositis is a common complication of cancer treatment that may negatively impact the patient's cancer treatment outcome. Despite its frequency and consequences, the lack of effective interventions has frustrated patients and caregivers. Fortunately, a broad range of mechanistically targeted compounds are being developed.
Authors: R M Vasconcelos; N Sanfilippo; B J Paster; A R Kerr; Y Li; L Ramalho; E L Queiroz; B Smith; S T Sonis; P M Corby Journal: J Dent Res Date: 2016-04-06 Impact factor: 6.116
Authors: James L Alexander; Ian D Wilson; Julian Teare; Julian R Marchesi; Jeremy K Nicholson; James M Kinross Journal: Nat Rev Gastroenterol Hepatol Date: 2017-03-08 Impact factor: 46.802
Authors: Thaís Bianca Brandão; Karina Morais-Faria; Ana Carolina Prado Ribeiro; César Rivera; João Victor Salvajoli; Marcio Ajudarte Lopes; Joel B Epstein; Praveen R Arany; Gilberto de Castro; Cesar Augusto Migliorati; Alan Roger Santos-Silva Journal: Support Care Cancer Date: 2018-02-08 Impact factor: 3.603
Authors: Ana Gabriela Costa Normando; Camila Lopes Rocha; Isabela Porto de Toledo; Paulo Tadeu de Souza Figueiredo; Paula Elaine Diniz Dos Reis; Graziela De Luca Canto; Eliete Neves Silva Guerra Journal: Support Care Cancer Date: 2017-06-16 Impact factor: 3.603
Authors: Rafaela Maia Almendra Mattos; Regina Maria Holanda de Mendonça; Simone Dos Santos Aguiar Journal: Support Care Cancer Date: 2019-05-23 Impact factor: 3.603
Authors: Maria C E Andersen; Malene W Johansen; Thomas Nissen; Anders B Nexoe; Gunvor I Madsen; Grith L Sorensen; Uffe Holmskov; Anders Schlosser; Jesper B Moeller; Steffen Husby; Mathias Rathe Journal: Support Care Cancer Date: 2020-09-12 Impact factor: 3.603